Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS

British Journal of Pharmacology

Volumn 172, Issue 6, 2015, Pages 1397-1414

  Papapetropoulos, Andreas ^a   Hobbs, Adrian J ^b   Topouzis, Stavros ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTIINFLAMMATORY AGENT; ATACIGUAT; CINACIGUAT; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GSK 2181236A; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INORGANIC NITRITE; LIFICIGUAT; NAPROXCINOD; NCX 1015; NEURONAL NITRIC OXIDE SYNTHASE; NITRATE; NITRIC OXIDE; NITRIC OXIDE DONATING ANTIINFLAMMATORY AGENT; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE V; RIOCIGUAT; SILDENAFIL; SOLUBLE GUANYLATE CYCLASE; SOLUBLE GUANYLATE CYCLASE STIMULATOR; TADALAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; CELL RECEPTOR; SOLUBLE GUANYLYL CYCLASE;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; BECKER MUSCULAR DYSTROPHY; BIOSYNTHESIS; BRAIN EDEMA; BROWN ADIPOSE TISSUE; CARDIOVASCULAR SYSTEM; CATALYSIS; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; COMBINATION CHEMOTHERAPY; CONFORMATIONAL TRANSITION; DIABETIC CARDIOMYOPATHY; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; ENERGY EXPENDITURE; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; HEART FAILURE; HUMAN; HYPERTENSION; LUNG FIBROSIS; METABOLIC REGULATION; MOLECULAR DYNAMICS; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REPERFUSION INJURY; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYSTOLIC HEART FAILURE; TRANSLATIONAL RESEARCH; UPREGULATION; WHITE ADIPOSE TISSUE; ANIMAL; CARDIOVASCULAR DISEASES; DRUG DESIGN; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CYCLIC GMP; DRUG DESIGN; GUANYLATE CYCLASE; HUMANS; MOLECULAR TARGETED THERAPY; NITRIC OXIDE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 84923804984     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12980     Document Type: Review

References (182)

1. Adamo CM, Dai DF, Percival JM, Minami E, Willis MS, Patrucco E, et al. (2010). Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 107: 19079-19083.
2. Ahrens I, Habersberger J, Baumlin N, Qian H, Smith BK, Stasch JP, et al. (2011). Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC. Atherosclerosis 218: 431-434.
3. Alderton WK, Cooper CE, Knowles RG, (2001). Nitric oxide synthases: structure, function and inhibition. Biochem J 357: 593-615.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ligand-gated ion channels. Br J Pharmacol 170: 1582-1606.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14:Nuclear hormone receptors. Br J Pharmacol 170: 1652-1675.
7. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
8. Alkaitis MS, Crabtree MJ, (2012). Recoupling the cardiac nitric oxide synthases: tetrahydrobiopterin synthesis and recycling. Curr Heart Fail Rep 9: 200-210.
9. Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, et al. (2006). 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 14: 1193-1201.
10. Bach A, Clausen BH, Møller M, Vestergaard B, Chi CN, Round A, et al. (2012). A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage. Proc Natl Acad Sci U S A 109: 3317-3322.
11. Baliga RS, MacAllister RJ, Hobbs AJ, (2011). New perspectives for the treatment of pulmonary hypertension. Br J Pharmacol 163: 125-140.
12. Baliga RS, Milsom AB, Ghosh SM, Trinder SL, Macallister RJ, Ahluwalia A, et al. (2012). Dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase. Circulation 125: 2922-2932.
13. Bandarage UK, Janero DR, (2001). Nitric oxide-releasing nonsteroidal anti-inflammatory drugs: novel gastrointestinal-sparing drugs. Mini Rev Med Chem 1: 57-70.
14. Bartelt A, Heeren J, (2014). Adipose tissue browning and metabolic health. Nat Rev Endocrinol 10: 24-36.
15. Basu S, Grubina R, Huang J, Conradie J, Huang Z, Jeffers A, et al. (2007). Catalytic generation of N2O3 by the concerted nitrite reductase and anhydrase activity of hemoglobin. Nat Chem Biol 3: 785-794.
16. Belge C, Hammond J, Dubois-Deruy E, Manoury B, Hamelet J, Beauloye C, et al. (2014). Enhanced expression of β3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. Circulation 129: 451-462.
17. Bender AT, Beavo JA, (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58: 488-520.
18. Biel M, Michalakis S, (2007). Function and dysfunction of CNG channels: insights from channelopathies and mouse models. Mol Neurobiol 35: 266-277.
19. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC Jr, (2007). Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 49: 1128-1133.
20. Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, et al. (2013). Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128: 502-511.
21. Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessì-Fulgheri P, Zhang C, et al. (2012). Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest 122: 1022-1036.
22. Bratasz A, Selvendiran K, Wasowicz T, Bobko A, Khramtsov VV, Ignarro LJ, et al. (2008). NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols. J Transl Med 26: 9.
23. Bubb KJ, Trinder SL, Baliga RS, Patel J, Clapp LH, MacAllister RJ, et al. (2014). Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension. Circulation 130: 496-507.
24. Bucci M, Gratton J-P, Rudic RD, Acevedo L, Roviezzo F, Cirino G, et al. (2000). In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 6: 1362-1367.
25. Burley DS, Ferdinandy P, Baxter GF, (2007). Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol 152: 855-869.
26. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. (2010a). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9: 77-93.
27. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. (2010b). Care Considerations Working Group, Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9: 177-189.
28. Buys ES, Cauwels A, Raher MJ, Passeri JJ, Hobai I, (2009). sGC(alpha)1(beta)1 attenuates cardiac dysfunction and mortality in murine inflammatory shock models. J Physiol 297: 654-663.
29. Cao J, Viholainen JI, Dart C, Warwick HK, Leyland ML, Courtney MJ, (2005). The PSD95-nNOS interface: a target for inhibition of excitotoxic p38 stress-activated protein kinase activation and cell death. J Cell Biol 168: 117-126.
30. Caplin B, Leiper J, (2012). Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators? Arterioscler Thromb Vasc Biol 32: 1343-1353.
31. Casey DB, Badejo AM Jr, Dhaliwal JS, Murthy SN, Hyman AL, Nossaman BD, et al. (2009). Pulmonary vasodilator responses to sodium nitrite are mediated by an allopurinol-sensitive mechanism in the rat. Am J Physiol Heart Circ Physiol 96: H524-H533.
32. Castro LR, Verde I, Cooper DM, Fischmeister R, (2006). Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 113: 2221-2228.
33. Cauwels A, Brouckaert P, (2011). Nitrite regulation of shock. Cardiovasc Res 89: 553-559.
34. Cauwels A, Buys ES, Thoonen R, Geary L, Delanghe J, (2009). Nitrite protects against morbidity and mortality associated with TNF- or LPS-induced shock in a soluble guanylate cyclase-dependent manner. J Exp Med 206: 2915-2924.
35. Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, et al. (2007). Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369: 1621-1626.
36. Chaudhary SC, Singh T, Kapur P, Weng Z, Arumugam A, Elmets CA, et al. (2013). Nitric oxide-releasing sulindac is a novel skin cancer chemopreventive agent for UVB-induced photocarcinogenesis. Toxicol Appl Pharmacol 268: 249-255.
37. Clark RS, Kochanek PM, Obrist WD, Wong HR, Billiar TR, Wisniewski SR, et al. (1996). Cerebrospinal fluid and plasma nitrite and nitrate concentrations after head injury in humans. Crit Care Med 24: 1243-1251.
38. Conole D, Scott LJ, (2013). Riociguat: first global approval. Drugs 73: 1967-1975.
39. Conti M, Beavo J, (2007). Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76: 481-511.
40. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, et al. (2003). Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 9: 1498-1505.
41. Costell MH, Ancellin N, Bernard RE, Zhao S, Upson JJ, Morgan LA, et al. (2012). Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress. Front Pharmacol 3: 1-14.
42. le Cras TD, Xue C, Rengasamy A, Johns RA, (1996). Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. Am J Physiol 270: 164-170.
43. Croom KF, Curran MP, Abman SH, Channick RN, Heresi GA, Rubin LJ, et al. (2008). Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs 68: 383-397.
44. Cunnington C, Van Assche T, Shirodaria C, Kylintireas I, Lindsay AC, Lee JM, et al. (2012). Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation 125: 1356-1366.
45. Da J, Chen L, Hedenstierna G, (2007). Nitric oxide up-regulates the glucocorticoid receptor and blunts the inflammatory reaction in porcine endotoxin sepsis. Crit Care Med 35: 26-32.
46. Derbyshire E, Marletta MA, (2012). Structure and regulation of soluble guanylate cyclase. Annu Rev Biochem 81: 533-559.
47. Doyle MP, Pickering RA, DeWeert TM, Hoekstra JW, Pater D, (1981). Kinetics and mechanism of the oxidation of human deoxyhemoglobin by nitrites. J Biol Chem 256: 12393-12398.
48. Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A, (2007). Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol 572: 12-22.
49. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, et al. (2011). Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478: 103-109.
50. Erdmann E, Semigran MJ, Nieminen MS, Gheorghiade M, Agrawal R, Mitrovic V, et al. (2013a). Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J 34: 57-67.
51. Erdmann J, Stark K, Esslinger UB, Rumpf PM, Koesling D, Wit C, et al. (2013b). Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature 504: 432-436.
52. Erusalimsky JD, Moncada S, (2007). Nitric oxide and mitochondrial signaling: from physiology to pathophysiology. Arterioscler Thromb Vasc Biol 227: 2524-2531.
53. Evgenov OV, Pacher P, Schmidt PM, Haskõ G, Schmidt HH, Stasch JP, (2006). NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5: 755-768.
54. Farrell AJ, Blake DR, Palmer RMJ, Moncada S, (1992). Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 51: 1219-1222.
55. Fiorucci S, Distrutti E, (2011). COXIBs, CINODs and H2S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs. Curr Med Chem 18: 3494-3505.
56. Fiorucci S, Antonelli E, Distrutti E, Del Soldato P, Flower RJ, Clark MJ, et al. (2002). NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc Natl Acad Sci U S A 99: 15770-15775.
57. Fiorucci S, Santucci L, Distrutti E, (2007). NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon. Dig Liver Dis 39: 1043-1051.
58. Follmann M, Griebenow N, Hahn MG, Hartung I, Mais F-J, Mittendorf J, et al. (2013). The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem Int Ed Engl 52: 9442-9462.
59. Förstermann U, Li H, (2011). Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol 164: 213-223.
60. Francis SH, Busch JL, Corbin JD, Sibley D, (2010). cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 62: 525-563.
61. Friebe A, Mergia E, Dangel O, Lange A, Koesling D, (2007). Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase. Proc Natl Acad Sci U S A 104: 7699-7704.
62. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. (2009). Tadalafil therapy for pulmonary arterial hypertension. Circulation 119: 2894-2903.
63. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. (2011). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 34: 1219-1263.
64. Garcia-Cardena G, Fan R, Stern DF, Liu J, Sessa WC, (1996). Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J Biol Chem 271: 27237-27240.
65. Geschka S, Kretschmer A, Sharkovska Y, Evgenov OV, Lawrenz B, Hucke A, et al. (2011). Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS ONE 6: e21853.
66. Gheorghiade M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD, et al. (2012). Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail 14: 1056-1066.
67. Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Bohm M, et al. (2013). Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev 18: 123-134.
68. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. (2013a). Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369: 319-329.
69. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. (2013b). Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369: 330-340.
70. Ghosh A, Stuehr DJ, (2012). Soluble guanylyl cyclase requires heat shock protein 90 for heme insertion during maturation of the NO-active enzyme. Proc Natl Acad Sci U S A 109: 1298-3003.
71. Ghosh SM, Kapil V, Fuentes-Calvo I, Bubb KJ, Pearl V, Milsom AB, et al. (2013). Enhanced vasodilator activity of nitrite in hypertension: critical role for erythrocytic xanthine oxidoreductase and translational potential. Hypertension 61: 1091-1102.
72. Giaid A, Saleh D, (1995). Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333: 214-221.
73. Giannetta E, Isidori AM, Galea N, Carbone I, Mandosi E, Vizza CD, et al. (2012). Chronic inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 125: 2323-2333.
74. Graham DY, Chan FKL, (2008). NSAIDs, risks, and gastroprotective strategies: current status and future. Gastroenterology 134: 1240-1246.
75. Guazzi M, Vicenzi M, Arena R, Guazzi MD, (2011). PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 4: 8-17.
76. Guazzi M, Vicenzi M, Arena R, (2012). Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. Eur J Heart Fail 14: 82-90.
77. Guo DC, Regalado E, Casteel DE, Santos-Cortez RL, Gong L, Kim JJ, et al. (2013). Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections. Am J Hum Genet 93: 398-404.
78. Hållström L, Berghäll E, Frostell C, Sollevi A, Soop AL, (2008). Nitric oxide inhalation and glucocorticoids as combined treatment in human experimental endotoxemia. Crit Care Med 36: 3043-3047.
79. Hendgen-Cotta UB, Merx MW, Shiva S, Schmitz J, Becher S, Klare JP, et al. (2008). Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischemia-reperfusion injury. Proc Natl Acad Sci U S A 105: 10256-10261.
80. Hill MD, Martin RH, Mikulis D, Wong JH, Silver FL, Terbrugge KG, et al. (2012). Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 11: 942-950.
81. Hoenicka M, Becker EM, Apeler H, Sirichoke T, Schröder H, Gerzer R, et al. (1999). Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. J Mol Med (Berl) 77: 14-23.
82. Hoeper MM, Halank M, Wilkens H, Günther A, Weimann G, Gebert I, et al. (2013). Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J 41: 853-860.
83. Hoffmann J, Goadsby PJ, (2012). New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS inhibitors. Curr Treat Options Neurol 14: 50-59.
84. Hoffmann LS, Schmidt PM, Keim Y, Hoffmann C, Schmidt HHHW, Stasch J-P, (2011). Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells. PLoS ONE 6: e23596.
85. Hofmann F, Feil R, Kleppisch T, Schlossmann J, (2006). Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev 86: 1-23.
86. Høivik HO, Laurijssens BE, Harnisch LO, Twomey CK, Dixon RM, Kirkham AJ, et al. (2010). Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 30: 1458-1467.
87. Høye KLB, Harnisch LO, Twomey CK, Dixon RM, Kirkham AJ, Williams PM, et al. (2009). Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for 12 weeks in the prophylactic treatment of migraine. Cephalalgia 29: 132.
88. Hunter CJ, Dejam A, Blood AB, Shields H, Kim-Shapiro DB, Machado RF, et al. (2004). Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nat Med 10: 1122-1127.
89. Ichinose F, Roberts JD Jr, Zapol WM, (2004). Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation 109: 3106-3111.
90. Jones NC, Constantin D, Gibson CL, Prior MJ, Morris PG, Marsden CA, et al. (2004). A detrimental role for nitric oxide synthase-2 in the pathology resulting from acute cerebral injury. J Neuropathol Exp Neurol 63: 708-720.
91. Kamisaki Y, Saheki S, Nakane M, Palmieri JA, Kuno T, Chang BY, et al. (1986). Soluble guanylate cyclase from rat lung exists as a heterodimer. J Biol Chem 261: 7236-7241.
92. Kapil V, Milsom AB, Okorie M, Maleki-Toyserkani S, Akram F, Rehman F, et al. (2010a). Inorganic nitrate supplementation lowers blood pressure in humans: role for nitrite-derived NO. Hypertension 56: 274-281.
93. Kapil V, Webb AJ, Ahluwalia A, (2010b). Inorganic nitrate and the cardiovascular system. Heart 96: 1703-1709.
94. Keravis T, Lugnier C, (2012). Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol 165: 1288-1305.
95. Khong SM, Andrews KL, Huynh NN, Venardos K, Aprico A, Michell DL, et al. (2012). Arginase II inhibition prevents nitrate tolerance. Br J Pharmacol 166: 2015-2023.
96. Klinger JR, (2007). The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 28: 143-167.
97. Kukreja RC, Salloum FN, Das A, Koka S, Ockaili RA, Xi L, (2011). Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. Exp Clin Cardiol 16: e30-e35.
98. Lang M, Kojonazarov B, Tian X, Kalymbetov A, Weissmann N, Grimminger F, et al. (2012). The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS ONE 7: e43433.
99. Larsen FJ, Ekblom B, Sahlin K, Lundberg JO, Weitzberg E, (2006). Effects of dietary nitrate on blood pressure in healthy volunteers. N Engl J Med 355: 2792-2793.
100. Leiper J, Nandi M, (2011). The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat Rev Drug Discov 10: 277-291.
101. Li H, Förstermann U, (2013). Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease. Curr Opin Pharmacol 13: 161-167.
102. Lima B, Forrester MT, Hess DT, Stamler JS, (2010). S-nitrosylation in cardiovascular signaling. Circ Res 106: 633-646.
103. Linder AE, McCluskey LP, Cole KR III, Lanning KM, Webb RC, (2005). Dynamic association of nitric oxide downstream signaling molecules with endothelial caveolin-1 in rat aorta. J Pharmacol Exp Ther 314: 9-15.
104. Lõpez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, et al. (2004). Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32: 21-30.
105. Lundberg JO, Weitzberg E, Gladwin MT, (2008). The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 7: 156-167.
106. Lundberg JO, Gladwin MT, Ahluwalia A, Benjamin N, Bryan NS, Butler A, et al. (2009). Nitrate and nitrite in biology, nutrition and therapeutics. Nat Chem Biol 5: 865-869.
107. Martin EA, Barresi R, Byrne BJ, Tsimerinov EI, Scott BL, Walker AE, et al. (2012). Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci Transl Med 4: 155-162.
108. Martin F, Baskaran P, Ma X, Dunten PW, Schaefer M, Stasch JP, et al. (2010). Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase. J Biol Chem 285: 22651-22657.
109. Millar TM, Stevens CR, Benjamin N, Eisenthal R, Harrison R, Blake DR, (1998). Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions. FEBS Lett 427: 225-228.
110. Morris SM Jr, (2009). Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol 157: 922-930.
111. Münzel T, Daiber A, Ullrich V, Mülsch A, (2005). Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler Thromb Vasc Biol 25: 1551-1557.
112. Nathan C, (1997). Inducible nitric oxide synthase: what difference does it make? J Clin Invest 100: 2417-2423.
113. Nausch LW, Ledoux J, Bonev AD, Nelson MT, Dostmann WR, (2008). Differential patterning of cGMP in vascular smooth muscle cells revealed by single GFP-linked biosensors. Proc Natl Acad Sci U S A 105: 365-370.
114. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, et al. (2003). Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 299: 896-899.
115. Oess S, Icking A, Fulton D, Govers R, Müller-Esterl W, (2006). Subcellular targeting and trafficking of nitric oxide synthases. Biochem J 396: 401-409.
116. Oliver JJ, Hughes VE, Dear JW, Webb DJ, (2010). Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. Hypertension 56: 62-67.
117. Palmer JE, Guillard FL, Laurijssens BE, Wentz AL, Dixon RM, Williams PM, et al. (2009). A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia 29: 124.
118. Paul-Clark MJ, Roviezzo F, Flower RJ, Cirino G, Soldato PD, Adcock IM, et al. (2003). Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J Immunol 171: 3245-3252.
119. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
120. Pellicena P, Karow DS, Boon EM, Marletta MA, Kuriyan J, (2004). Crystal structure of an oxygen-binding heme domain related to soluble guanylate cyclases. Proc Natl Acad Sci U S A 101: 12854-12859.
121. Pfeifer A, Klatt P, Massberg S, Ny L, Sausbier M, Hirneiss C, et al. (1998). Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J 17: 3045-3051.
122. Phillips PG, Long L, Wilkins MR, Morrell NW, (2005). cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodelling. Am J Physiol Lung Cell Mol Physiol 288: L103-L115.
123. Piggott LA, Hassell KA, Berkova Z, Morris AP, Silberbach M, Rich TC, (2006). Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular compartments. J Gen Physiol 128: 3-14.
124. Purohit R, Fritz BG, The J, Issaian A, Weichsel A, David CL, et al. (2014). YC-1 binding to the beta subunit of the soluble guanylyl cyclase overcomes allosteric inhibition by the alpha subunit. Biochemistry 53: 101-114.
125. Ranieri VM, Thompson BT, Barie PS, Dhainaut J-F, Douglas IS, (2012). Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366: 2055-2064.
126. Rassaf T, Ferdinandy P, Schulz R, (2014). Nitrite in organ protection. Br J Pharmacol 171: 1-11.
127. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. (2013). Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309: 1268-1277.
128. Rinecker M, Plesnila N, Baethmann A, Stoffel M, (2003). Secondary growth of a cortical necrosis: effect of NOS inhibition by aminoguanidine post insult. Acta Neurochir (Wien) 145: 977-981.
129. Roberts JD, Polaner DM, Lang P, Zapol WM, (1992). Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340: 818-819.
130. Rosen RC, Kostis JB, (2003). Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 92: 9M-18M.
131. Rosenzweig EB, (2010). Tadalafil for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 11: 127-132.
132. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM, (1993). Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 328: 399-405.
133. Rudyk O, Phinikaridou A, Prysyazhna O, Burgoyne JR, Botnar RM, Eaton P, (2013). Protein kinase G oxidation is a major cause of injury during sepsis. Proc Natl Acad Sci U S A 110: 9909-9913.
134. Sakurai H, Kohsaka W, Liu MF, Higashiyama H, Hirata Y, Kanno K, et al. (1995). Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest 96: 2357-2363.
135. Sansbury BE, Cummins TD, Tang Y, Hellmann J, Holden CR, Harbeson MA, et al. (2012). Overexpression of endothelial nitric oxide synthase prevents diet-induced obesity and regulates adipocyte phenotype. Circ Res 111: 1176-1189.
136. Sayed N, Kim DD, Fioramonti X, Iwahashi T, Duran WN, Beuve A, (2008). Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance. Circ Res 103: 606-614.
137. Schäfer A, Fraccarollo D, Werner L, Bauersachs J, (2010). Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. Pharmacol Res 62: 432-438.
138. Schermuly RT, Pullamsetti SS, Kwapiszewska G, Dumitrascu R, Tian X, Weissmann N, et al. (2007). Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation 115: 2331-2339.
139. Schermuly RT, Stasch JP, Pullamsetti SS, Middendorff R, Müller D, Schlüter KD, et al. (2008). Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 32: 881-891.
140. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F, (2011). Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 8: 443-455.
141. Schindler U, Strobel H, Schönafinger K, Linz W, Löhn M, Martorana PA, et al. (2006). Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. Mol Pharmacol 69: 1260-1268.
142. Schmidt PM, Schramm M, Schröder H, Wunder F, Stasch JP, (2004). Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J Biol Chem 279: 3025-3032.
143. Seymour M, Pétavy F, Chiesa F, Perry H, Lukey PT, Binks M, et al. (2012). Ultrasonographic measures of synovitis in an early phase clinical trial: a double-blind, randomised, placebo and comparator controlled phase IIa trial of GW274150 (a selective inducible nitric oxide synthase inhibitor) in rheumatoid arthritis. Clin Exp Rheumatol 30: 254-261.
144. Shemyakin A, Kövamees O, Rafnsson A, Böhm F, Svenarud P, Settergren M, et al. (2012). Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation 126: 2943-2950.
145. Siddiqi N, Bruce M, Neil CJ, Jagpal B, Maclennon G, Cotton SC, et al. (2013). Protocol: does sodium nitrite administration reduce ischaemia-reperfusion injury in patients presenting with acute ST segment elevation myocardial infarction? Nitrites in acute myocardial infarction (NIAMI). J Transl Med 11: 116.
146. Singh D, Richards D, Knowles RG, Schwartz S, Woodcock A, Langley S, et al. (2007). Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am J Respir Crit Care Med 176: 988-993.
147. del Soldato P, Sorrentino R, Pinto A, (1999). NO-aspirins: a class of new antiinflammatory and antithrombotic agents. Trends Pharmacol Sci 20: 319-323.
148. Starr A, Hussein D, Nandi M, (2013). The regulation of vascular tetrahydrobiopterin bioavailability. Vascul Pharmacol 58: 219-230.
149. Stasch J-P, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, (2002). NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136: 773-783.
150. Stasch JP, Evgenov OV, (2013). Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol 218: 279-313.
151. Stasch JP, Hobbs AJ, (2009). NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 191: 277-308.
152. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, Arun Kumar HS, Meurer S, et al. (2006). Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116: 2552-2561.
153. Stasch JP, Pacher P, Evgenov OV, (2011). Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123: 2263-2273.
154. Stefanovic-Racic MS, Stadler J, Evans CH, (1993). Nitric oxide and arthritis. Arthritis Rheum 36: 1036-1044.
155. Straub AC, Lohman AW, Billaud M, Johnstone SR, Dwyer ST, Lee MY, et al. (2012). Endothelial cell expression of haemoglobin α regulates nitric oxide signalling. Nature 491: 473-477.
156. Tamargo J, Lõpez-Sendõn J, (2011). Novel therapeutic targets for the treatment of heart failure. Nat Rev Drug Discov 10: 536-555.
157. Taylor RW, Zimmerman JL, Dellinger RP, Straube RC, Criner GJ, Davis K Jr, et al. (2004). Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. J Am Med Assoc 291: 1603-1609.
158. Terpolilli NA, Zweckberger K, Trabold R, Schilling L, Schinzel R, Tegtmeier F, et al. (2009). The novel nitric oxide synthase inhibitor 4-amino-tetrahydro-L-biopterine prevents brain edema formation and intracranial hypertension following traumatic brain injury in mice. J Neurotrauma 26: 1963-1975.
159. Tian X, Vroom C, Ghofrani AH, Weissmann N, Bieniek E, Grimminger F, (2011). Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling. PLoS ONE 6: e18136.
160. Tiso M, Tejero J, Basu S, Azarov I, Wang X, Simplaceanu V, et al. (2011). Human neuroglobin functions as a redox-regulated nitrite reductase. J Biol Chem 286: 18277-18289.
161. Tsai EJ, Kass DA, (2009). Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther 122: 216-238.
162. Turesin F, Del Soldato P, Wallace JL, (2003). Enhanced anti-inflammatory potency of a nitric oxide-releasing derivative of prednisolone in the rat. Br J Pharmacol 139: 966-972.
163. Vandendriessche B, Rogge E, Goossens V, Vandenabeele P, Stasch JP, Brouckaert P, et al. (2013). The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems. PLoS ONE 8: e72155.
164. Vermeersch P, Buys E, Pokreisz P, Marsboom G, Ichinose F, Sips P, (2007). Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia. Circulation 116: 936-943.
165. Vosatka RJ, Kashyap S, Trifiletti RR, (1994). Arginine deficiency accompanies persistent pulmonary hypertension of the newborn. Biol Neonate 66: 65-70.
166. Wallace JL, Rizzo G, Cirino G, Del Soldato P, Fiorucci S, (2004). Enhanced anti-inflammatory potency of a nitric oxide-releasing derivative of flunisolide: role of nuclear factor-kappaB. J Pharmacol Exp Ther 310: 1096-1102.
167. Webb A, Bond R, McLean P, Uppal R, Benjamin N, Ahluwalia A, (2004). Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proc Natl Acad Sci U S A 101: 13683-13688.
168. Webb AJ, Milsom AB, Rathod KS, Chu WL, Qureshi S, Lovell MJ, et al. (2008a). Mechanisms underlying erythrocyte and endothelial nitrite reduction to nitric oxide in hypoxia: role for xanthine oxidoreductase and endothelial nitric oxide synthase. Circ Res 103: 957-964.
169. Webb AJ, Patel N, Loukogeorgakis S, Okorie M, Aboud Z, Misra S, et al. (2008b). Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension 51: 784-790.
170. Weber M, Lauer N, Mulsch A, Kojda G, (2001). The effect of peroxynitrite on the catalytic activity of soluble guanylyl cyclase. Free Radic Biol Med 31: 1360-1367.
171. Weissmann N, Hackemack S, Dahal BK, Pullamsetti SS, Savai R, Mittal M, et al. (2009). The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol 297: 658-665.
172. White WB, Schnitzer TJ, Bakris GL, Frayssinet H, Duquesroix B, Weber M, (2011). Effects of naproxcinod on blood pressure in patients with osteoarthritis. Am J Cardiol 107: 1338-1345.
173. Williams JL, Kashfi K, Ouyang N, del Soldato P, Kopelovich L, Rigas B, (2004). NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem Biophys Res Commun 313: 784-788.
174. Winger JA, Marletta MA, (2005). Expression and characterization of the catalytic domains of soluble guanylate cyclase: interaction with the heme domain. Biochemistry 44: 4083-4090.
175. Wolfe MM, Lichtenstein DR, Singh G, (1999). Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888-1899.
176. Wu CC, Ko FN, Kuo SC, Lee FY, Teng CM, (1995). YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 116: 1973-1978.
177. Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, Goggans T, et al. (2004). Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 18: 1746-1748.
178. Zhang M, Kass DA, (2011). Phosphodiesterases and cardiac cGMP: evolving roles and controversies. Trends Pharmacol Sci 32: 360-365.
179. Zhang Z, Naughton D, Winyard PG, Benjamin N, Blake DR, Symons MC, (1998). Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity. Biochem Biophys Res Commun 249: 767-772.
180. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW, et al. (2010). A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 363: 620-628.
181. Zuckerbraun BS, Shiva S, Ifedigbo E, Mathier MA, Mollen KP, Rao J, et al. (2010). Nitrite potently inhibits hypoxic and inflammatory pulmonary arterial hypertension and smooth muscle proliferation via xanthine oxidoreductase-dependent nitric oxide generation. Circulation 121: 98-109.
182. Zwolinska-Wcislo M, Brzozowski T, Ptak-Belowska A, Targosz A, Urbanczyk K, Kwiecien S, et al. (2011). Nitric oxide-releasing aspirin but not conventional aspirin improves healing of experimental colitis. World J Gastroenterol 17: 4076-4089.